Eli Lilly (LLY)

MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.

IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.

XLV concentrates on 61 large-cap S&P 500 names, while FHLC casts a wider net with 365 holdings across mid and small caps. Both charge 0.08% annually.

Bristol Myers Squibb is facing a sizable patent cliff, but that's not unusual in the pharma sector.

Tech stocks are selling off as investors question the payoff of artificial intelligence (AI) infrastructure spending.

These drugmakers are capitalizing on their pipeline successes.

Eli Lilly's commitment to philanthropy, coupled with a dedication to environmental progress, make it a sustainability leader.

Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.

These companies make up about 20% of the index.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.

Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants.

VHT's 411 holdings and 0.09% expense ratio deliver identical 5-year returns to IYH's concentrated 100-stock portfolio, raising questions about whether lower costs justify broader diversification.

The company may lean on its core therapeutic area to help it overcome recent headwinds.

Biotech and pharma stocks, tracked by the iShares Biotechnology ETF, have shown relative strength amid the tech sell-off, with Eli Lilly and Pfizer standing out as top performers.

The market has rewarded this biotech for its breakthroughs.

Its leading investigational drug demonstrated relatively high levels of weight loss in a late-stage clinical trial.

The pharmaceutical industry is relatively less correlated to the rest of the economy, and that's a diversification benefit for investors.

On Oct. 20, 2026, major U.S. indexes gained as falling oil prices boosted blue chips and semiconductors edged upwards.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Eli Lilly is growing quickly, lowering realized prices, and building its next wave of drugs. Here's what the numbers say about margins, valuation, and the catalysts that matter next.

Is this company the biggest dark horse in the chronic weight management space?

AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.

Polls suggest a divided government after the midterms, a scenario that historically benefits healthcare stocks. Here's how the XLV and IHF ETFs compare for investors eyeing the sector.